Novo Nordisk Faces July 29 PDUFA for Mim8 in Hemophilia A

Novo Nordisk (NVO) faces a July 29 PDUFA date for denecimig (Mim8), an investigational bispecific antibody for subcutaneous prophylaxis in hemophilia A patients with or without inhibitors. The BLA is supported by the FRONTIER clinical program.

Update September 4, 2026 (Friday): Mim8 remains unapproved as of September 4. Now 27 business days past the July 29 PDUFA (July 30, 31, August 3, 4, 5, 6, 7, 10, 11, 12, 13, 14, 17, 18, 19, 20, 21, 24, 25, 26, 27, 28, 31, September 1, 2, 3, 4). Drugs.com still lists “FDA Approved: No.” and Novo Nordisk has issued no press release. NVO closed at $47.51 on September 3 (Polygon), down 1.4% from the $48.18 article reference price. The degree of silence continues to suggest either an undisclosed review-clock extension or extended labeling negotiations.

Update September 3, 2026 (Thursday): Mim8 remains unapproved as of September 3. Now 26 business days past the July 29 PDUFA (July 30, 31, August 3, 4, 5, 6, 7, 10, 11, 12, 13, 14, 17, 18, 19, 20, 21, 24, 25, 26, 27, 28, 31, September 1, 2, 3). Drugs.com still lists “FDA Approved: No.” and Novo Nordisk has issued no press release. NVO closed at $46.77 on September 2 (Polygon), down 2.9% from the $48.18 article reference price. The degree of silence continues to suggest either an undisclosed review-clock extension or extended labeling negotiations.

Update September 2, 2026 (Wednesday): Mim8 remains unapproved as of September 2. Now 25 business days past the July 29 PDUFA (July 30, 31, August 3, 4, 5, 6, 7, 10, 11, 12, 13, 14, 17, 18, 19, 20, 21, 24, 25, 26, 27, 28, 31, September 1, 2). Drugs.com still lists “FDA Approved: No.” and Novo Nordisk has issued no press release. NVO closed at $45.12 on September 1 (Polygon), down 6.4% from the $48.18 article reference price. The degree of silence continues to suggest either an undisclosed review-clock extension or extended labeling negotiations.

Update August 31, 2026 (Monday): Mim8 remains unapproved as of August 31. Now 23 business days past the July 29 PDUFA (July 30, 31, August 3, 4, 5, 6, 7, 10, 11, 12, 13, 14, 17, 18, 19, 20, 21, 24, 25, 26, 27, 28, 31). Drugs.com still lists “FDA Approved: No.” and Novo Nordisk has issued no press release. NVO closed at $45.61 on August 28 (Polygon; the August 31 session has not opened). The degree of silence continues to suggest either an undisclosed review-clock extension or extended labeling negotiations.

Update August 28, 2026 (Friday): Mim8 remains unapproved as of August 28. Now 22 business days past the July 29 PDUFA (July 30, 31, August 3, 4, 5, 6, 7, 10, 11, 12, 13, 14, 17, 18, 19, 20, 21, 24, 25, 26, 27, 28). Drugs.com still lists “FDA Approved: No.” and Novo Nordisk has issued no press release. The degree of silence continues to suggest either an undisclosed review-clock extension or extended labeling negotiations. GILD BIC/LEN was approved as Bixlenvo on August 27 on its PDUFA date (see our Bixlenvo coverage).

Update August 27, 2026 (Thursday): Mim8 remains unapproved as of August 27. Now 21 business days past the July 29 PDUFA (July 30, 31, August 3, 4, 5, 6, 7, 10, 11, 12, 13, 14, 17, 18, 19, 20, 21, 24, 25, 26, 27). Drugs.com still lists “FDA Approved: No.” and Novo Nordisk has issued no press release. NVO closed at $46.26 on August 27 (Polygon), down 4.0% from the $48.18 article reference price. The degree of silence continues to suggest either an undisclosed review-clock extension or extended labeling negotiations.

Update August 25, 2026 (Tuesday): Mim8 remains unapproved as of August 25. Now 19 business days past the July 29 PDUFA (July 30, 31, August 3, 4, 5, 6, 7, 10, 11, 12, 13, 14, 17, 18, 19, 20, 21, 24, 25). Drugs.com still lists “FDA Approved: No.” and Novo Nordisk has issued no press release. NVO closed at $46.74 on August 21 (Polygon; Aug 24 close not yet available), down 3.0% from the $48.18 article reference price. The degree of silence continues to suggest either an undisclosed review-clock extension or extended labeling negotiations. JAZZ Ziihera PDUFA is today (Aug 25) and GILD BIC/LEN follows Aug 27.

Update August 24, 2026 (Monday):

Update August 21, 2026 (Friday): Mim8 remains unapproved as of August 21. Now 17 business days past the July 29 PDUFA (July 30, 31, August 3, 4, 5, 6, 7, 10, 11, 12, 13, 14, 17, 18, 19, 20, 21). This is the longest Q3 2026 PDUFA overrun by an enormous margin — nearly a month with no FDA communication. Drugs.com still lists “FDA Approved: No.” and Novo Nordisk has issued no press release. NVO closed at $46.14 on August 20 (Polygon), down 4.2% from the $48.18 article reference price and down 3.3% from the $47.73 August 10 close. The stock continues to be driven by GLP-1 dynamics and the July 31 ZEUS/ziltivekimab Phase 3 failure rather than the Mim8 delay. This degree of silence increasingly suggests either an undisclosed review-clock extension or extended labeling negotiations.

Update August 11, 2026 (Tuesday): Mim8 remains unapproved as of August 11. Now 9 business days past the July 29 PDUFA (July 30, 31, August 3, 4, 5, 6, 7, 10, 11). August 1, 2, 8, and 9 were weekends and do not count. This is the longest Q3 2026 PDUFA overrun by a wide margin — 9 business days with no FDA communication is extremely unusual and increasingly suggests either a pending Complete Response Letter, an undisclosed clock extension, or extended labeling negotiations. Drugs.com still lists “FDA Approved: No.” NVO closed at $47.73 on August 10 (Polygon; Aug 11 close not yet available from Polygon), down 0.9% from the $48.18 article reference price. The stock continues to be driven by GLP-1 dynamics rather than the Mim8 delay.

Update August 9, 2026 (Sunday): Mim8 remains unapproved as of August 9. The prior update incorrectly stated “8 business days” — the correct count is 7 business days past the July 29 PDUFA (July 30, 31, August 3, 4, 5, 6, 7). August 1 is a Saturday and does not count as a business day. No FDA announcement is expected on a weekend. The next opportunity is Monday August 10 (8th business day). Drugs.com still lists “FDA Approved: No.” NVO closed at $47.26 on August 7 (Polygon), down 1.9% from the $48.18 article reference price.

Update July 31, 2026: The July 29 PDUFA date has now passed by two days. As of July 31, no FDA approval announcement has been made. Drugs.com still lists Mim8 as “FDA Approved: No.” Novo Nordisk has not issued a press release. The delay is unusual — PDUFA dates are goal dates, not deadlines, but a two-day delay with no communication is notable. The FDA may issue a delayed approval, a Complete Response Letter, or request additional information. NVO closed at $47.08 on July 31 (Polygon), down from the $48.18 article reference price.

Update August 1, 2026: As of August 1, Mim8 remains unapproved. Drugs.com still lists “FDA Approved: No.” No press release from Novo Nordisk. The three-day delay past the PDUFA date is increasingly notable but not unprecedented — the FDA can extend review without public communication. NVO closed at $47.08 on July 31 (Polygon), down 2.3% from the $48.18 article reference. The stock is being driven by GLP-1 dynamics rather than the Mim8 delay. Monitor Novo Nordisk’s IR page and the FDA’s approval list for updates. The next content refresh run will check again.

Update August 2, 2026: Mim8 remains unapproved as of August 2 (Sunday). The PDUFA date of July 29 has now passed by 2 business days (July 30 and July 31) — the longest delay in Q3 2026. Drugs.com still lists “FDA Approved: No.” No press release from Novo Nordisk. The market is closed for the weekend. The next opportunity for an FDA announcement is Monday August 3. This delay pattern is unusual and may indicate the FDA is requesting additional data or reviewing labeling negotiations. NVO remains at $47.08 (July 31 Polygon close).

Update August 3, 2026: As of Monday August 3 (pre-market), Mim8 remains unapproved. Drugs.com still lists “FDA Approved: No.” The PDUFA date of July 29 has now passed by 3 business days (July 30, July 31, and August 3). This is the longest delay in Q3 2026 and increasingly unusual — the FDA can extend review without public communication, but a 3-business-day delay past a PDUFA date typically signals labeling negotiations or a request for additional data. If no announcement comes by the end of August 3, the delay extends to 4 business days (next check: August 4). NVO remains at $47.08 (July 31 Polygon close). The US market opens at 9:30 AM ET.

Update August 7, 2026: Mim8 remains unapproved as of August 7 — now 7 business days past the July 29 PDUFA (July 30, 31, August 3, 4, 5, 6, 7). This is the longest Q3 2026 PDUFA overrun by a wide margin and increasingly unusual. Drugs.com still lists “FDA Approved: No.” Novo Nordisk has issued no press release. Seven business days with no communication suggests either labeling negotiations, an extension of the review clock, a discipline review, or a pending Complete Response Letter. The FDA typically does not delay this long without some form of communication. NVO continues to be driven by GLP-1 dynamics and the July 31 ZEUS/ziltivekimab Phase 3 failure rather than the Mim8 delay.

If approved, denecimig would be the first FVIIIa mimetic offering flexible dosing frequencies: once monthly, once every two weeks, or once weekly via a single-use pen. That flexibility supports personalized treatment, a meaningful differentiator in a market currently dominated by Roche’s Hemlibra (emicizumab).

What hemophilia A is and why inhibitor status matters

Hemophilia A is a genetic bleeding disorder caused by deficiency of Factor VIII, a protein needed for blood clotting. Patients with inhibitors develop antibodies against Factor VIII replacement therapy, making standard treatment ineffective. A therapy that works for both inhibitor and non-inhibitor populations addresses a broader patient group.

Denecimig is a bispecific antibody that mimics Factor VIIIa, bridging factors IXa and X to restore clotting function without requiring Factor VIII itself. The mechanism means it works regardless of inhibitor status.

The competitive picture

Roche’s Hemlibra is the current standard for subcutaneous hemophilia A prophylaxis. It requires weekly dosing and works for patients with inhibitors. Denecimig’s advantage would be flexible dosing frequency, including monthly and biweekly options, plus the single-use pen delivery system.

For patients on prophylaxis, fewer injections mean fewer clinic visits and less treatment burden. Monthly dosing could convert patients who find weekly injections burdensome. The single-use pen also simplifies administration compared with vial-and-syringe methods.

Novo Nordisk presented positive long-term safety and efficacy data from the FRONTIER4 extension study at the ISTH 2026 congress on July 11.

Market context

NVO closed at $48.18 on July 23, with volume of 8.18 million shares. The stock has been under pressure amid the broader GLP-1 competition between Novo Nordisk and Eli Lilly, with both companies recently filing lawsuits over advertising claims related to weight loss drugs.

A hemophilia approval would diversify Novo Nordisk’s revenue beyond the obesity and diabetes franchise that currently dominates its valuation. Rare disease hematology is a smaller market than obesity, but it carries higher margins and less direct competition.

For broader context on how large-cap pharma diversifies into specialty markets, see our coverage of GSK’s lung cancer approval.

Risks

The hemophilia A prophylaxis market is established, not greenfield. Hemlibra generated roughly $4.6 billion in 2025 revenue for Roche. Denecimig would need to demonstrate clear clinical or convenience advantages to win market share from a well-entrenched competitor.

Bleeding rates remain the key efficacy metric. If FRONTIER data does not show non-inferior or superior bleed reduction compared with Hemlibra, uptake will be slow regardless of dosing convenience. Long-term safety monitoring for thrombotic events is also standard for bispecific factor-mimicking antibodies.

What to watch next

The July 29 FDA decision. An approval would give Novo Nordisk a rare disease commercial entry and validate its diversification beyond metabolic disease. Payor coverage and pricing relative to Hemlibra will determine whether the flexible-dosing story translates into market share.

Hematology Advisor coverage | Novo Nordisk FRONTIER data via PR Newswire